Supplementary Figure 5 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Authors :: Gooitzen M. van Dam
Vasilis Ntziachristos
Elisabeth G.E. de Vries
Paul J. van Diest
Elsken Van der Wall
Willem P.Th.M. Mali
Arjen J. Witkamp
Sabrina Oliveira
Sjoerd G. Elias
Wouter B. Nagengast
Bert van der Vegt
Esther de Boer
Matthijs D. Linssen
Annelies Jorritsma-Smit
Carolien P. Schröder
Marjolijn N. Lub-de Hooge
Jakob de Vries
Liesbeth Jansen
Anton G.T. Terwisscha van Scheltinga
Mariëtte E.G. Kranendonk
Jürgen Glatz
Arthur L.L. Adams
Johannes S. de Jong
Maximillian Koch
Laetitia E. Lamberts
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Co-localization of Bevacizumab-IRDye800CW, hematoxylin / eosin (H/E), VEGF-A, Collagen and CD34 in Ductal Carcinoma In Situ (DCIS).

Full Text Access

Tools